Furthermore, in NSCLC with PD-L1 expression of 1–49%, the median OS of ICI monotherapy was significantly longer in the non-PD group (13.5 months [95% CI, 7.5–24.2]) than in the PD group (8.3 months [95% CI, 5.1–9.5]), with a p-value of 0.003 (Supplementary Figure 1B), while there was no significant difference in the PFS between the two groups (p = 0.473) (Supplementary Figure 1A). The gene discussed is CD274; the disease is non-small cell lung carcinoma.